BioCentury | Dec 19, 2019

Boehringer deal, clinical milestones support Bridge IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...
BC Extra | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

In the latest sign of success for Bridge's strategy to translate first-in-class compounds discovered in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877. The partnership is the second...
Items per page:
1 - 2 of 2